Pharma R&D Today

Ideas and Insight supporting all stages of Drug Discovery & Development

Select category
Search this blog

Lessons learned from the Covid vaccine development process

Posted on August 23rd, 2021 by in COVID-19

As the world’s focus has turned to getting the COVID-19 vaccines out as widely and rapidly as possible, it’s easy to almost forget about the incredible global effort that developed them in record time. But it is important to take some time to reflect on the process that got us here, so that we can learn from it and celebrate the amazing researchers whose work is now saving so many lives.

(more…)

Technology and empathy help make remote working a success for Elsevier

Posted on July 29th, 2021 by in Pharma R&D

We at Elsevier were pleased to be one of five companies recognized for their ability to keep remote workers rooted in company culture in this recent Comparably article. Like many organizations during the pandemic, we had to quickly adapt to remote working on a large scale for our international workforce. As the article notes, “Elsevier took an empathetic and pragmatic approach in supporting its people and its customers and rapidly harnessed technology to work from home.”

(more…)

An Update on Global Availability of COVID-19 Vaccines from Editor of The Lancet

Posted on June 11th, 2021 by in Pharma R&D

In the U.S., the COVID-19 vaccine roll-out has moved at a strong pace, with about half of Americans now having received at least one shot. While many of the most motivated people have been able to get vaccinated by now, plenty of others still have questions. They may wonder if the vaccines are safe in general, or safe for them personally if they have a particular condition. They may have been confronted with conflicting information about the efficacy of vaccines.

(more…)

COVID-19 Treatment Trial Reaches Out to Communities of Color

Posted on April 5th, 2021 by in COVID-19

An ongoing problem in clinical trials over the years has been a failure to procure diverse enough representation among the participants. For a long time, this was due to bias and oversight on the part of the research community, and the consequence was a lack of full understanding in how medications and treatments affected women and various racial/ethnic minorities.

(more…)

  1. 1
  2. 2
  3. 3
  4. 8